ADRIANA | α2B adrenoceptor antagonist

CAS:
 719277-27-7
Catalog Number:
 10-4369
ADRIANA chemical structure

Available Options

Size:PriceQuantity 
5 mg$80.00
25 mg$285.00
Request Quote / Bulk / Custom Size
Product Inquiry

ADRIANA (719277-27-7) is potent antagonist (IC50 = 1.71 µM) of the α2B adrenoceptor with selectivity over α2A and α2C.  It promotes noradrenaline release in the murine spinal dorsal horn leading to potent analgesic effects via stimulation of the α2A-dependent pain inhibitory pathway. Active in various nociceptive pain models in both mice and non-human primates. Orally bioavailable with no adverse cardiac/circulatory system effects.

References/Citations:

  1. Toyomoto et al. (2025), Discovery and development of an oral analgesic targeting the α2B adrenoceptor; Proc. Natl. Acad. Sci. USA 122 e2500006122
719277-27-7, ADRIANA, ADRIANA supplier, α2B adrenoceptor antagonist, α2B antagonist
CAS:
719277-27-7
Catalog Number:
10-4369
Activity:
α2B adrenoceptor antagonist
Chemical Names:
(Z)-1-(3-Ethyl-5-fluorobenzo[d]thiazol-2(3H)-ylidene)propan-2-one
Molecular Weight:
237.29
Molecular Formula:

C12H12FNOS

Solubility:
Soluble in DMSO (30 mg/ml)
Physical Properties:
Off-white solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

ADRIANA (719277-27-7) is potent antagonist (IC50 = 1.71 µM) of the α2B adrenoceptor with selectivity over α2A and α2C.  It promotes noradrenaline release in the murine spinal dorsal horn leading to potent analgesic effects via stimulation of the α2A-dependent pain inhibitory pathway. Active in various nociceptive pain models in both mice and non-human primates. Orally bioavailable with no adverse cardiac/circulatory system effects.

References/Citations:

  1. Toyomoto et al. (2025), Discovery and development of an oral analgesic targeting the α2B adrenoceptor; Proc. Natl. Acad. Sci. USA 122 e2500006122

STEM CELL

BOGO